GLAND PHARMA SHARE PRICE
Cancer drug prices revised from today; patients may save Rs 3,540 crore annually
The government has revised the prices of 1,364 anti-cancer medicine formulations effective from November 9. This decision aims to limit trade margins and reduce consumer costs for cancer drugs. According to official reports, this measure is expected to save consumers Rs 3,540.38 crore each year.
Gland Pharma shares jump 4% after Q2 profit jumps 58%, revenue rises 23% YoY
Gland Pharma shares rose 3.89% after reporting strong Q2 FY27 results, with revenue growing 23% and net profit jumping 58% year-on-year. The stock touched a 52-week high of Rs 3,345, supported by robust CDMO growth, improved margins, new product launches and increased US regulatory approvals.
AMFI reshuffle: Jio Platforms and NSE may get largecap status, Vedanta may become midcap in H1 CY27
Nuvama expects Jio Platforms and NSE to enter AMFI's largecap category in its H1 CY27 reshuffle, while Vedanta may move to midcap status. The proposed changes also include upgrades and downgrades across midcap and smallcap stocks, with revised market-cap thresholds estimated at Rs 1.12 lakh crore and Rs 36,700 crore.
Sai Life Sciences shares jump 9%, multibagger stock rallies 19% in 3 days after Q2 results. Why Jefferies hiked target price
Sai Life Sciences shares hit a fresh 52-week high on Monday after strong Q2 results and bullish brokerage commentary. Jefferies retained its Buy rating and raised its target price to Rs 2,050, citing healthy CRO and CDMO growth, a strengthening pipeline and improved earnings prospects.
Divi’s Laboratories shares gain another 5% after Q2 results. Here’s why Jefferies raised target price by 23%
Shares of Divi’s Laboratories jumped 5% following a 64% YoY surge in Q2 FY27 net profit to Rs 1,127 crore. Brokerage Jefferies raised its target price by 23% to Rs 12,550, citing robust CDMO business expansion, strong EBITDA margins, and a solid GLP peptide pipeline.
Divi's Labs shares jump 8% to fresh 52-week high after Q2 profit soars 64% YoY. What brokerages say after bumper results?
Divi’s Laboratories shares surged over 8% during Muhurat Trading, hitting a 52-week high after Q2 FY27 net profit jumped 64% to ₹1,127 crore. Revenue grew 35%, while brokerages differed on valuation concerns and future growth prospects.
- Go To Page 1
Top Nifty50 stocks analysts suggest buying in this volatile week
Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.
Sensex & Nifty fall in Muhurat trade for first time since 2017
Indian equities experienced a slight decline during the Diwali Muhurat trading session for the first time since 2017. The Sensex ended at 80,999.40, down 28.62 points, and the Nifty closed at 24,986.40, shedding 43.95 points. Despite the drop, market sentiment has recently shown signs of improvement, particularly with foreign investors becoming buyers again.
Muhurat Trading 2026: Which stocks to buy during special session today? Analysts list top technical picks
Investors are preparing for the Muhurat Trading session today, which marks the beginning of Samvat 2083. Stock exchanges BSE and NSE will hold the session for an hour starting at 2.20 pm. Analysts from HDFC Securities and Axis Securities have identified several stocks as top picks for this trading period. Stocks like HCL Technologies and IIFL Finance have been highlighted for their potential upside.
If AI unwinding pulls power stocks down, mind the difference between narrative and business: 6 stocks with upside potential of up to 30%
It is quite possible that, over the coming weeks, the narrative on the street could be that power stocks, which many had started to treat as a kind of proxy for the AI build-out, would come under pressure. But linking these stocks to global unwinding in the AI trade could be a mistake because demand for power in India depends on something far bigger and far older.
Cancer drug prices to fall by up to 96% from November 9; consumers set to save Rs 3,502 crore annually
Starting November 9, consumers in India will benefit from significantly reduced prices on 137 anti-cancer drugs. The government has capped trade margins on these medications, leading to an estimated annual savings of Rs 3,502.31 crore for consumers. Price reductions have been reported across 1,225 formulations, with some reductions exceeding 50 percent.
World War III alert? Why Iran is distributing 180,000 iodine tablets as Trump weighs fresh strikes on nuclear sites?
Iran has started distributing iodine tablets to residents of Bushehr to prepare for potential nuclear emergencies. This distribution, which prioritizes areas near the nuclear power plant, includes 180,000 total tablets. The World Health Organisation recommends these tablets to protect against radioactive iodine exposure. Authorities emphasize the importance of child and pregnant women protection during these emergencies. Tensions with the US continue, prompting increased emergency preparedness activities in the region.
These large-, mid- and small-cap stocks have upside potential of up to 31% in 1 year, according to analysts
In the last two years, the world has learnt that you can never quite predict what US President Trump will do next. Tomorrow, to pull attention one way or another, there could well be some more action against Iran, changing the mood again in a single afternoon. So, the improvement in sentiment is real, but it is also fragile.
Market wrap: Bajaj Finance, Shriram Finance, Apollo Hospital, ONGC top gainers and losers on Nifty and Sensex on Thursday
Indian equity markets staged a strong rally on Thursday, with the Sensex surging over 2,000 points and the Nifty jumping 576 points amid optimism following the US midterm election results. Bajaj Finance, Shriram Finance and M&M led the gainers, while Apollo Hospitals and ONGC featured among the top laggards.
Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports Plus
Stock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company analyses, the report also collates analysts’ forecasts and trend analysis for each component. An average score in Stock Reports Plus is calculated by undertaking quantitative analysis of five key investment tools – earnings, fundamentals, relative valuation, risk, and price momentum.
Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return
In 2026, India's pharmaceutical stocks are making headlines with impressive year-to-date gains. This surge is driven by strong domestic demand alongside enhanced profitability from new product launches. Notable players like Laurus Labs and Gland Pharma have recorded remarkable returns, topping 100%. Amid challenges faced by other sectors, the pharmaceutical field demonstrates resilience. Analysts are optimistic but advise exercising caution regarding potential market volatility and the durability of this sector's performance.
These mid-caps have ‘strong buy’ & ‘buy’ recos and upside potential of up to 28%, according to analysts
Global markets on Wednesday celebrated the outcome of the US mid-term election as well as a sharp drop in oil prices. Oil prices, which at the end of last week were at about $118 to the barrel, are now under $95. The hope clearly is that Democrat control of both chambers of the US Congress will pressure the Trump administration to pursue a diplomatic end to the conflict with Iran in the Gulf.
Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike; Jefferies raises target price by 8%
Emcure Pharma shares hit a 10% upper circuit after strong Q2 FY27 results prompted the company to raise its full-year growth guidance. Brokerages turned more positive, citing robust international business, improving domestic growth and a strong product pipeline.
Bonus issue alert! Last day to buy this Rakesh Jhunjhunwala-backed smallcap pharma stock for 1:1 bonus bonanza
As per Sebi's T+1 settlement cycle, investors must buy the company's shares at least one trading day before the record date for them to be credited to their demat accounts and qualify for the bonus issue. This makes today the last day to buy the stock to be eligible for the bonus shares.
High Court restrains NPPA from action against AstraZeneca
The Delhi High Court has issued a temporary restraining order against the NPPA's actions toward AstraZeneca Pharma. This order remains in effect until the next hearing date, January 11. AstraZeneca has argued that its product may not fall under controlled drug prices. The NPPA has accused AstraZeneca of overcharging for the inhaler from May 2016 to November 2025. AstraZeneca denies these allegations and claims compliance with the price regulations.
Market Trading Guide: Tata Steel among 5 stocks to buy on Tuesday for healthy returns
Indian equities experienced a strong start to the week, bolstered by better than expected Q2 earnings. Improved domestic macro indicators contributed to the positive sentiment among investors and traders. Increased passenger vehicle sales and gross GST collections reflected resilience in domestic economic activity. Several stock recommendations were highlighted for Tuesday, suggesting potential upward movements. Analysts shared technical insights indicating opportunities for buying various stocks in the current market.
Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports Plus
Stock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company analyses, the report also collates analysts’ forecasts and trend analysis for each component. An average score in Stock Reports Plus is calculated by undertaking quantitative analysis of five key investment tools – earnings, fundamentals, relative valuation, risk, and price momentum.
Top Nifty50 stocks analysts suggest buying in this volatile week
Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.
India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugs
Over the past four quarters, India's medicine sales have increased significantly due to rising demand in chronic care segments. The growth rate reached 12% year-on-year in the September quarter, showing a positive trend in the industry. Larger pharmaceutical companies have benefited from the shutdown of many non-compliant smaller units. Budgets were also boosted by a reduction in GST on medicines.
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%
The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosystem charge. And both the government and the courts have stepped in. At one level, that is not entirely a bad thing. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.
For investors with ability to look past the current bearish narrative: 5 large-cap stocks with upside potential of up to 34%
One stock not falling on bad news does not mean the worst is over for the whole market. It may mean only that the bears have, for now, taken out of that one stock all that they wanted to. The broader pressure can still come back. So this is a small positive, and it should be considered just that, and nothing more.
Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore
Mankind Pharma shares jumped nearly 8% after the company reported a 38% year-on-year rise in Q2 profit to Rs 716 crore. Revenue grew 17%, supported by domestic and export growth, while EBITDA margins expanded 210 basis points.
Load More
